The cascade of HIV care in British Columbia, Canada, 1996-2011: A population-based retrospective cohort study

The Lancet Infectious Diseases

Volumn 14, Issue 1, 2014, Pages 40-49

  Nosyk, Bohdan ^a,b   Montaner, Julio S G ^b   Colley, Guillaume ^b   Lima, Viviane D ^b   Chan, Keith ^b   Heath, Katherine ^b   Yip, Benita ^b   Samji, Hasina ^b   Gilbert, Mark ^b,c   Barrios, Rolando ^b,d   Gustafson, Réka ^d   Hogg, Robert S ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d VANCOUVER COASTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS LOAD;

EID: 84890428401     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70254-8     Document Type: Article

References (39)

1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996, 276:146-154.
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA 2010, 304:321-333.
3. 2010 ART guidelines for adults and adolescents-evidence map WHO, (accessed Nov 2, 2012). http://www.who.int/hiv/topics/treatment/evidence/en/index.html.
4. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2011, Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health & Human Services, Washington, DC, (accessed March 12, 2012). http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
5. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997, 349:1294.
6. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, ART Cohort Collaboration (ART-CC) groupsART Cohort Collaboration (ART-CC) groups.
7. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA 2012, 308:387-402.
8. Montaner JSG, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010, 376:532-539.
9. Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1-RNA concentrations and incidence of HIV-1 among injecting drug users: a prospective cohort study. BMJ 2009, 338:b1649.
10. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505. for the HPTN 052 study team.
11. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57.
12. Dieffenbach CW, Fauci AS Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 2009, 301:2380-2382.
13. Coates TJ, Richter L, Caceres C Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008, 372:669-684.
14. Granich R, Gupta S, Suthar A, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 2011, 9:446-469. for the ART in Prevention of HIV and TB Research Writing Group.
15. Burns DN, Dieffenbach CW, Vermund SH Rethinking prevention of HIV type-1 infection. Clin Infect Dis 2010, 51:725-731.
16. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011, 52:793-800.
17. Meeting report on framework for metrics to support effective treatment as prevention, 2-3 April 2012 Geneva, Switzerland 2012, WHO, World Health Organization, Geneva, (accessed Nov 12, 2012). http://www.who.int/iris/handle/10665/75387.
18. Eldred L, Malitz F Introduction to the supplemental issue on the HRSA SPNS outreach initiative. AIDS Patient Care STDS 2007, 21(suppl 1):S1-S2.
19. HIV and sexually transmitted infections 2010 British Columbia Centre for Disease Control, (accessed Oct 15, 2012). http://www.bccdc.ca/NR/rdonlyres/2035512C-DBEC-495B-A332-C410EE9520C7/0/CPS_Report_STI_HIV_2010_annual_report_FINAL_20111122.pdf.
20. Hogg RS, Heath K, Lima VD, et al. Disparities in the burden of HIV/AIDS in Canada. PLoS One 2012, 7:e47260.
21. Nosyk B, Colley G, Chan K, et al. Application of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. PLoS One 2013, 8:e54416. for the STOP HIV/AIDS Study Team.
22. Monitoring HIV care in the United States: a strategy for generating national estimates of HIV care and coverage 2012, Institute of Medicine, The National Academies Press, Washington, DC.
23. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care Panel. Ann Intern Med 2012, 156:817-833.
24. HAB HIV core clinical performance measures for adult/adolescent clients: group 1 US Department of Health & Human Services, Health Resources and Services AdministrationHealth Resources and Services Administration, (accessed Feb 12, 2013). http://hab.hrsa.gov/deliverhivaidscare/files/habgrp1pms08.pdf.
25. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342:921-929. for the RAKAI project study group.
26. Lima VD, Le A, Nosyk B, et al. Development and assessment of a composite programme assessment score for initial HIV therapy. PLoS One 2012, 7:e47859.
27. Nosyk B, Min JE, Lima VD, Yip B, Hogg RS, Montaner JSG HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011. J Acquir Immune Defic Syndr 2013, 63:653-659. on behalf of the STOP HIV/AIDS Study Group.
28. HIV in the United States: the stages of care US Centers for Disease Control and Prevention, (accessed Feb 3, 2013). http://www.cdc.gov/nchhstp/newsroom/docs/2012/Stages-of-CareFactSheet-508.pdf.
29. Demers V, Melo M, Jackevicius C, et al. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures. CMAJ 2008, 178:405-409.
30. Johnston SS, Juday T, Seekins D, Espindle D, Chu BC Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV. J Manag Care Pharm 2012, 18:129-145.
31. Das-Douglas M, Riley ED, Ragland K, et al. Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions. AIDS Behav 2009, 13:1-9.
32. Tripathi A, Youmans E, Gibson JJ, Duffus WA The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study. AIDS Res Hum Retroviruses 2011, 27:751-758.
33. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.
34. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
35. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004, 292:251-265.
36. Mugavero MJ, Davila JA, Nevin CR, Giordano TP From access to engagement: measuring retention in outpatient HIV clinical care. AIDS Patient Care STDS 2010, 24:607-613.
37. Chen M, Rhodes PH, Hall HI, Kilmarx PH, Branson BM, Valleroy LA Prevalence of undiagnosed HIV infection among persons aged ≥13 years-National HIV surveillance system, United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2012, 61(suppl):57-64.
38. Althoff KN, Buchacz K, Hall HI, et al. US trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med 2012, 157:325-335. for the North American AIDS Cohort Collaboration on Research and Design.
39. Yang Q, Boulos D, Yan P, et al. Estimates of the number of prevalent and incident human immunodeficiency virus (HIV) infections in Canada, 2008. Can J Public Health 2010, 101:486-490.